Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


Cardiovascular diseases occupy a leading position in morbidity, mortality and disability in most countries. Ischemic heart disease and stroke lead in the structure of mortality from cardiovascular diseases. The issues of lipid-lowering therapy with statins in the aspect of stroke prevention are discussed in the article. The main risk factors of atherosclerosis and their prevalence are presented. Topical standards for statin use, evidence-based medicine data obtained in randomized clinical trials, and evidence from actual clinical practice are covered. Possible promising areas of statin use for the prevention of acute cerebrovascular accident are also considered. Combination therapy together with other lipid-lowering drugs, as well as drugs of other pharmacological groups, the use of statins from earlier ages, the practical implementation of pleiotropic effects of statins can be attributed to the latter. The authors clearly demonstrate that the actual practice of using statins lags significantly behind the ideal, reflected in the recommendations and randomized clinical trials. Adherence to medical recommendations is one of the key factors in this. The main factors that can influence the increase of adherence of patients to taking statins and increase the effectiveness of their application in real clinical practice are presented.

About the Authors

O. V. Gaisenok
Joint Hospital and Polyclinic, Administrative Department of the President of the Russian Federation
Russian Federation

MD, PhD, Head of Department of General Cardiology, 

Michurinskiy prosp. 6, Moscow, 119285

A. N. Rozhkov
Central State Medical Academy, Administrative Department of the President of the Russian Federation
Russian Federation

MD, Resident, Chair of Therapy, Cardiology and Functional Diagnostics with the Course of Nephrology, 

Marshala Timoshenko ul. 19-1A, Moscow, 121359 

A. S. Lishuta
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

MD, PhD, Associate Professor, Chair of Hospital Therapy №1, 

Trubetskaya ul., 8-2, Moscow, 119991 


1. Atlas Writing Group. European Society of Cardiology: Cardiovascular Disease Statistics 2017. Eur Heart J. 2018;39(7):508-579. doi: 10.1093/eurheartj/ehx628.

2. Heart Disease and Stroke Statistics—2017 Update. A Report From the American Heart Association. Circulation. 2017;135:e146-e603. doi: 10.1161/CIR.0000000000000485.

3. Gaisenok O.V. Scientific session of the general meeting of the members of the RAS "Scientific fundamentals of the effectiveness and safety of medicines". Available at: obraniya-chlenov-RAN-Nauchnye/. Checked by Apr 23, 2018 (In Russ.) [Гайсенок О.В. Научная сессия общего собрания членов РАН «Научные основы эффективности и безопасности лекарственных средств». Доступно на: Проверено 23.04.2018].

4. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295(2):180-9. doi:10.1001/jama.295.2.180

5. Gaisenok OV, Martsevich SY, Kalashnikov SV, et al. The role of duplex scanning of the carotid arteries in the detection of correlations between carotid and coronary atherosclerosis by the results of coronaroangiography in patients with stable angina. Ter Arkhiv. 2012;84(4):35-8. (In Russ.) [Гайсенок О.В., Марцевич С.Ю., Калашников С.В., и др. О роли дуплексного сканирования сонных артерий в выявлении корреляции между каротидным и коронарным атеросклерозом по результатам коронароангиографии у пациентов со стабильной стенокардией. Терапевтический Архив. 2012;4:35-8].

6. Gaisenok O.V., Martsevich S.Yu., Kalashnikov S.Yu., et al. Evaluation of the information content of duplex scanning of carotid arteries in the framework of a comprehensive method of verification of the diagnosis of IHD in practical public health. Profilakticheskaja Medicina. 2012; 15 (6): 41-5 (In Russ.) [Гайсенок О.В., Марцевич С.Ю., Калашников С.Ю., и др. Оценка информативности дуплексного сканирования сонных артерий в рамках комплексной методики верификации диагноза ИБС в практическом здравоохранении. Профилактическая Медицина. 2012;15(6):41-5].

7. Heiss G, Sharrett AR, Barnes R, et al. Carotid atherosclerosis measured by B-mode ultrasound in populations: associations with cardiovascular risk factors in the ARIC study. Am J Epidemiol. 1991;134(3):250-6.

8. O'Leary DH, Polak JF, Kronmal RA et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 1999;340:14-22. doi: 10.1056/NEJM199901073400103.

9. Bots ML, Hoes AW, Koudstaal PJ et al. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation. 1997;96(5):1432-7. doi: 10.1161/01.CIR.96.5.1432.

10. Dijk JM, van der Graat G, Bots ML et al. Carotid intima-media thickness and the risk of new vascular events in patients with manifest atherosclerotic disease: the SMART study. Eur Heart J. 2006; 24:1971-8. doi: 10.1093/eurheartj/ehl136.

11. Maslyuk OA, Smolentseva IG, Amosova NA, et al. The hospital registry of a stroke in a specialized department for patients with acute impairment of cerebral circulation. Saratovskij Nauchno-Medicinskij Zhurnal. 2014;10(4):819-23. (In Russ.) [Маслюк О.А., Смоленцева И.Г., Амосова Н.А. и др. Госпитальный регистр инсульта в специализированном отделении для больных с острым нарушением мозгового кровообращения. Саратовский Научно-медицинский Журнал. 2014;10(4): 819-23].

12. Cosentino F, Rubattu S, Savoia C. Endothelial dysfunction and stroke. J Cardiovasc Pharmacol. 2001;38 Suppl 2:S75-8.

13. Knottnerus IL, Ten Cate H, Lodder J, et al. Endothelial dysfunction in lacunar stroke: a systematic review. Cerebrovasc Dis. 2009;27(5):519-26. doi: 10.1159/000212672.

14. Roquer J, Segura T, Serena J, Castillo J. Endothelial dysfunction, vascular disease and stroke: the ARTICO study.Cerebrovasc Dis. 2009;27 Suppl 1:25-37. doi: 10.1159/000200439.

15. Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with Atorvastatin to the National Cholesterol Educational Program Goal Versus ‘Usual’ Care in Secondary Coronary Heart Disease Prevention The GREek atorvastatin and Coronaryheart-disease Evaluation (GREACE)Study. Current Medical Research and Opinion. 2002;18(4):220-28.

16. Collins R, Armitage J, Parish S, et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363:757-67. doi: 10.1016/S0140-6736(04)15690-0.

17. Pedersen TR, Kjekshus J, Pyorala K, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study. (4S). Am J Cardiol. 1998;81:3335. doi: 10.1016/S0002-9149(97)00904-1.

18. Sever P.S., Dahlof B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Drugs. 2004; 64 Suppl 2:43-60.

19. Byington R.P., Davis B.R., Plehn J.F., et al. The Prospective Pravastatin Pooling (PPP) Project. Circulation. 2001;103:387-92. doi: 10.1161/01.CIR.103.3.387.

20. Ridker PM. Moving toward new statin guidelines in a post-JUPITER world: principles to consider. Curr Atheroscler Rep. 2009;11(4):249-56.

21. Amarenco P, Goldstein LB, Szarek M, et al. Effects of Intense Low-Density Lipoprotein Cholesterol Reduction in Patients With Stroke or Transient Ischemic Attack. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial. Stroke. 2007;38:3198-3204. doi: 10.1161/STROKEAHA.107.493106.

22. Sillesen H, Amarenco P, Hennerici MG, et al. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. 2008;39:3297-302. doi: 10.1161/STROKEAHA.108.516450.

23. Flint AC, Kamel H, Navi BB, et al. Statin Use During Ischemic Stroke Hospitalization Is Strongly Associated With Improved Poststroke Survival. Stroke. 2012;43(1):147-54. doi: 10.1161/STROKEAHA.111.627729.

24. Ní Chróinín D, Asplund K, Åsberg S, et al. Statin Therapy and Outcome After Ischemic Stroke. Stroke. 2013;44:448-456. doi: 10.1161/STROKEAHA.112.668277.

25. Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet. 2011;378:1231-43. doi: 10.1016/S0140-6736(11)61215- 4.

26. Bhatt D.L., Steg P.G., Ohman E.M. et al.; REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295:180—9. doi: 10.1001/jama.295.2.180.

27. Susekov AV, Zubareva M.Yu., Deev AD, et al. The main results of the Moscow Statin Survey (MSS). Serdtse. 2006;(6):324-8 (In Russ.) [Сусеков А В, Зубарева М.Ю, Деев А.Д, и др. Основные результаты Московского Исследования по Статинам (Moscow Statin Survey, MSS). Сердце. 2006;(6):324-8].

28. Oganov RG, Kukharchuk VV, Arutyunov GP, et al. Persistent dyslipidemia in statin-treated patients: Russian real-world clinical practice data (Russian part of the DYSIS Study). Cardiovascular Therapy and Prevention. 2012;4:70-8 (In Russ.) [Оганов Р.Г., Кухарчук В.В., Арутюнов Г.П., и др. Сохраняющиеся нарушения показателей липидного спектра у пациентов с дислипидемией, получающих статины, в реальной клинической практике в российской федерации (Российская часть исследования DYSIS). Кардиоваскулярная Терапия и Профилактика. 2012;4:70-8].

29. Martsevich S.Y., Ginzburg M.L., Kutishenko N.P., et al. The LIS study (Lyubertsy study of mortality in patients with acute myocardial infarction). Evaluation of the pharmacotherapy. Part 1. Treatment of patients before myocardial infarction and its influence on hospital mortality rate. Rational Pharmacotherapy in Cardiology. 2012;8(5):681-4. (In Russ.) (In Russ.) [Марцевич С.Ю., Гинзбург М.Л., Кутишенко Н.П., и др. Исследование ЛИС (Люберецкое Исследование Смертности больных, перенесших острый инфаркт миокарда). Оценка лекарственной терапии. Часть 1. Как лечатся больные перед инфарктом миокарда, и как это влияет на смертность в стационаре. Рациональная Фармакотерапия в Кардиологии. 2012;8(5):681-4]. doi:10.20996/1819-6446- 2012-8-5-681-684

30. Martsevich S.Y., Kutishenko N.P., Suvorov A.Y., et al. Characteristics of patients with cerebral stroke or transient ischemic attack, included into the LIS-2 register (Lyubertsy study of mortality in patients after stroke). Rational Pharmacotherapy in Cardiology. 2015;11(1):18-24. (In Russ.) [Марцевич С.Ю., Кутишенко Н.П., Суворов А.Ю. и др. Характеристика пациентов с мозговым инсультом или транзиторной ишемической атакой, включенных в регистр ЛИС-2. Рациональная Фармакотерапия в Кардиологии. 2015;11(1):18-24]. doi: 10.20996/1819-6446-2015-11-1-18-24.

31. Boytsov S.A., Loukianov M.M., Yakushin S.S., et al. Drug treatment of patients with the history of acute stroke: data of the pilot phase of the outpatient registry «REGION». Rational Pharmacotherapy in Cardiology. 2017;13(3):346-356. (In Russ.) [Бойцов С.А., Лукьянов М.М., Якушин С.С., и др. Медикаментозное лечение больных, перенесших острое нарушение мозгового кровообращения: данные пилотного этапа амбулаторного регистра «РЕГИОН». Рациональная Фармакотерапия в Кардиологии. 2017;13(3):346-56]. doi: 10.20996/1819-6446-2017- 13-3-346-356.

32. Order of Ministry of HC&SD №1740n 29.12.2012 «About Approval of Specialized Medical Care Standards for patients with brain infarction». Available at: Checked 23.04.2017. (In Russ.) [Приказ Минздравсоцразвития РФ № 1740н от 29 декабря 2012 года «Об утверждении стандарта специализированной медицинской помощи при инфаркте мозга». Доступно на: Проверено 23.04.2017].

33. Order of Ministry of HC&SD №513 01.08.2007 «About Approval of Medical Care Standard for patients with stroke». (In Russ.). Available at: Checked 08.01.2018. (In Russ.) [Приказ Минздравсоцразвития России №513 от 1 августа 2007 г. «Об утверждении стандарта медицинской помощи больным с инсультом». Доступно на: Проверено 08.01. 2018 ]

34. Pitt B., Waters D., Brown W.V. et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med. 1999;341:70-6.

35. Kini AS, Baber U, Kovacic JC, Changes in plaque lipid content after short-term intensive versus standard statin therapy: the YELLOW trial (reduction in yellow plaque by aggressive lipid-lowering therapy). J Am Coll Cardiol. 2013;62(1):21-9. doi: 10.1016/j.jacc.2013.03.058.

36. Ference B.A., Yoo W., Alesh I., et al. Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease. A Mendelian Randomization Analysis. J Am Coll Cardiol 2012; 60(25): 2631-9. doi:10.1016/j.jacc.2012.09.017

37. Drapkina O.M. Combination therapy of high-risk patients in real clinical practice. Results of Synergy study. Part 1. Antihypertensive branch. Rational Pharmacotherapy in Cardiology. 2017;13(2):155- 63. (In Russ.) [Драпкина О.М. Комбинированная терапия пациентов высокого риска в условиях реальной клинической практики. Результаты исследования синергия. Часть 1. Антигипертензивная ветвь. Рациональная Фармакотерапия в Кардиологии. 2017;13(2):155-63]. doi:10.20996/1819-6446-2017-13-2-155-163

38. Drapkina O.M., Lishuta A.S. Using a combination of perindopril, indapamide and rosuvastatin in the treatment of patients with hypertension and dyslipidemia. Rational Pharmacotherapy in Cardiology. 2017;13(4):454-62. (In Russ.) [Драпкина О.М., Лишута А.С. Использование комбинации периндоприла, индапамида и розувастатина в лечении пациентов с артериальной гипертензией и дислипидемией. Рациональная Фармакотерапия в Кардиологии. 2017;13(4):454-62]. doi:10.20996/1819-6446-2017-13-4-454-462

39. Kato T, Node K. Docosahexaenoic Acid with a statin and endothelial function in patients with coronary artery disease. J Atheroscler Thromb. 2015;22(5):440-1. doi: 10.5551/jat.ED014.

40. Zhang L, Gong D, Li S, Zhou X. Meta-analysis of the effects of statin therapy on endothelial function in patients with diabetes mellitus. Atherosclerosis. 2012;223(1):78-85. doi: 10.1016/j.atherosclerosis.2012.01.031.

41. Westerink J, Deanfield JE, Imholz BP, et al. High-dose statin monotherapy versus low-dose statin/ezetimibe combination on fasting and postprandial lipids and endothelial function in obese patients with the metabolic syndrome: The PANACEA study. Atherosclerosis. 2013;227(1):118-24. doi: 10.1016/j.atherosclerosis.2012.11.028.

42. Sarkar K, Sinha AK, Mehta JL. The role of statins in endothelial dysfunction in hypertension. Curr Opin Cardiol. 2006;21(4):316-21.

43. Filip-Ciubotaru FM, Manciuc C, Foia L. Statins and endothelial dysfunction. Rev Med Chir Soc Med Nat Iasi. 2009;113(4):975-83.

44. Gong X, Ma Y, Ruan Y, Fu G, Wu S. Long-term atorvastatin improves age-related endothelial dysfunction by ameliorating oxidative stress and normalizing eNOS/iNOS imbalance in rat aorta. Exp Gerontol. 2014;52:9-17. doi: 10.1016/j.exger.2014.01.015.

45. Park J, Hwang I, Kim SJ, et al. Atorvastatin prevents endothelial dysfunction in high glucose condition through Skp2-mediated degradation of FOXO1 and ICAM-1.Biochem Biophys Res Commun. 2017 Aug 9. pii: S0006-291X(17)31568-1. doi: 10.1016/j.bbrc.2017.08.023.

46. Garg N, Krishan P, Syngle A. Rosuvastatin improves endothelial dysfunction in ankylosing spondylitis. Clin Rheumatol. 2015;34(6):1065-71. doi: 10.1007/s10067-015-2912-3

47. Oganov RG, Kukharchuk VV, Arutyunov GP, et al on behalf of the DYSIS Study Group. Persistent dyslipidemia in statin-treated patients: Russian real-world clinical practice data (Russian part of the DYSIS Study). Cardiovascular Therapy and Prevention. 2012;11(4):70-8. (In Russ.) [Оганов Р. Г., Кухарчук В. В., Арутюнов Г. П., и др. от имени исследователей DYSIS. Сохраняющиеся нарушения показателей липидного спектра у пациентов с дислипидемией, получающих статины, в реальной клинической практике в российской федерации (российская часть исследования DYSIS). Кардиоваскулярная Терапия и Профилактика. 2012;11(4):70-8].

48. Joshua S. Benner, Robert J. Glynn, Helen Mogun, et al. Long-term Persistence in Use of Statin Therapy in Elderly Patients. JAMA. 2002;288(4):455-61. doi:10.1001/jama.288.4.455

49. Hinchcliffe A. Patient Adherence to Treatment with Statins for the Prevention of Cardiovascular Disease. Cardiff: Public Health Wales NHS Trust; 2011.

50. Jackevicius CA, Mamdani M, Tu JV. Adherence With Statin Therapy in Elderly Patients With and Without Acute Coronary Syndromes. JAMA. 2002;288(4):462-7. doi:10.1001/jama.288.4.462

51. Mantel-Teeuwisse AK, Goettsch WG, Klungel OH, et al. Long term persistence with statin treatment in daily medical practice. Heart. 2004;90(9):1065-6. doi: 10.1136/hrt.2003.026187

52. Mann DM, Woodward M, Muntner P, et al. Predictors of nonadherence to statins: A systematic review and meta-analysis. Ann Pharmacother. 2010;44(9):1410-21. doi: 10.1345/aph.1P150.

53. Gaisenok O., Martsevich S., Tripkosh S., Lukina Y. Analysis of lipid-lowering therapy and factors affecting regularity of statin intake in patients with cardiovascular disease enrolled in the PROFILE registry. Rev Port Cardiol. 2015;34 (2):111-6. doi: 10.1016/j.repc.2014.08.021.

54. Muhlestein JB, Horne BD, Bair TL, et al. Usefulness of in hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reducing mortality. Am J Cardiol. 2001;87:257-61. doi: 10.1016/S0002-9149(00)01354-0

55. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipidlowering therapy. Arch Intern Med. 2005;165(10):1147-52. doi: 10.1001/archinte.165.10.1147

56. Martsevich S.Yu., Gaisenok O. V., Tripkosh S. G., et al. Medical supervision in specialized center and the quality of lipid-lowering therapy in patients with cardiovascular diseases (according to the PROFILE register). Rational Pharmacotherapy in Cardiology. 2013;9 (2):133-137. (In Russ.) [Марцевич C. Ю., Гайсенок О. В., Трипкош С. Г., и др. Наблюдение в специализированном медицинском центре и качество гиполипидемической терапии у пациентов с сердечно-сосудистыми заболеваниями (по данным регистра ПРОФИЛЬ). Рациональная Фармакотерапия в Кардиологии. 2013;9(2):133-7]. doi: 10.20996/1819-6446-2013-9-2-133-137

57. Ageev FT, Fofanova TV, Smirnova MD, et al. Application of methods of technical impact on adherence to therapy in patients with cardiovascular diseases in outpatient practice. The results of the yearly observation. Serdtse. 2012;11(2):67-71. (In Russ.) [Агеев Ф.Т., Фофанова Т.В., Смирнова М.Д., и др. Применение методов технического воздействия на приверженность терапии у больных сердечно-сосудистыми заболеваниями в амбулаторной практике. Итоги годичного наблюдения. Сердце. 2012;11(2):67-71].

58. Temnikova E.A. To the question of the role of the social environment in increasing adherence to the therapy of outpatient patients of senile age. Serdtse. 2012;11(2):72-7. (In Russ.) [Teмникова E.A. К вопросу о роли социального окружения в повышении приверженности к терапии амбулаторных пациентов старческого возраста. Сердце. 2012. 11(2):72-7].

59. Schedlbauer A, Davies P, Fahey T. Interventions to improve adherence to lipid lowering medication. Cochrane Database Syst Rev. 2010;(3):CD004371. doi: 10.1002/14651858.CD004371.pub4.


For citations:

Gaisenok O.V., Rozhkov A.N., Lishuta A.S. HYPOLIPIDEMIC THERAPY IN STROKE PREVENTION: EXISTING STANDARDS, EVIDENCE-BASED MEDICINE DATA AND REAL PRACTICE. Rational Pharmacotherapy in Cardiology. 2018;14(3):434-440. (In Russ.)

Views: 742

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)